Mucopolysaccharidosis I (MPS I) (Hurler syndrome): Market View

This reports provides a data-driven overview of the current and future competitive landscape in Mucopolysaccharidosis I (Hurler syndrome) Therapeutics.

• In 2024, there were more than 1,740 diagnosed prevalent cases of MPS I in the 16 countries covered in GlobalData's epidemiology forecast.
• Currently, only one FDA-approved innovator drug is available for the treatment of MPS I.
• The MPS I pipeline holds 16 molecules, with only one molecule present in Phase III development.
• Over the past 10 years, commercial sponsors headed trials for MPS I, led by ArmaGen (four trials).
• Over the past decade, partnership have constituted a significant portion of transactions in North America, Europe, and the Asia-Pacific (APAC) region.

Scope

GlobalData's Mucopolysaccharidosis I (Hurler syndrome) Therapeutics: Competitive Landscape combines data from the Pharma Intelligence Center with in-house analyst expertise to provide a competitive assessment of the disease marketplace.

Components of the report include -

• Disease Landscape
• Disease Overview
• Epidemiology Overview
• Treatment Overview
• Marketed Products Assessment
• Breakdown by Mechanism of Action, Route of Administration
• Product Profiles with Sales Forecast
• Pricing and Reimbursement Assessment
• Annual Therapy Cost
• Time to Pricing and Time to Reimbursement
• Pipeline Assessment
• Breakdown by Development Stage, Mechanism of Action, Molecule Type, Route of Administration
• Product Profiles with Sales Forecast
• Late-to-mid-stage Pipeline Drugs
• Phase Transition Success Rate and Likelihood of Approval
• Clinical Trials Assessment
• Breakdown of Trials by Phase, Status, Virtual Components, Sponsors, Geography, and Endpoint Status
• Enrolment Analytics, Site Analytics, Feasibility Analysis
• Deals Landscape
• Mergers, Acquisitions, and Strategic Alliances by Region
• Overview of Recent Deals
• Commercial Assessment
• Key Market Players
• Future Market Catalysts

Reasons to Buy

• Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipeline.
• Develop business strategies by understanding the trends shaping and driving the Mucopolysaccharidosis I (Hurler syndrome) Therapeutics market.
• Drive revenues by understanding the key trends, innovative products and technologies, and companies likely to impact the global Mucopolysaccharidosis I (Hurler syndrome) Therapeutics market in the future.
• Formulate effective sales and marketing strategies by understanding the competitive landscape and analyzing the performance of various competitors.
• Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
• Organize your sales and marketing efforts by identifying the market categories that present the maximum opportunities for consolidations, investments, and strategic partnerships.